News

The Manila Times6d
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...
The Manila Times7d
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...